Fierce Biotech outlines criteria for its 2026 Fierce 15 list, spotlighting top innovators

The Fierce Biotech editorial team released its 2026 Fierce 15 list and discussed the selection process on a recent episode of "The Top Line" podcast.

More than 150 high‑quality entries were reviewed and narrowed down to fifteen companies that the team says have unusually high ambitions across a range of therapeutic areas.

Among the highlighted firms, Infinimmune secured a $75 million Series A round to advance its antibody platform, while Sanofi‑backed Expedition raised $115 million in a Series B to move its COPD drug into Phase 2. Beacon also earned attention for a pivotal trial that could lead to FDA approval of a gene therapy for a rare vision‑loss condition.

The discussion frames the Fierce 15 as a barometer of current biotech innovation, and the podcast invites listeners to explore the full list and related topics further.